Compare ClearPoint Neuro Inc (CLPT) vs MobilEye Global Inc (MBLY) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

MBLY trades at $9.75, up 2.09% today, with a bullish technical signal and strong analyst support (57.69% buy ratings). The company reported Q1 2026 EPS of $0.12, beating expectations, but faces profitability challenges with a net income margin of -203.97% for 2026. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it beyond traditional ADAS supply.

The outlook hinges on MBLY's execution of its robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. While near-term fundamentals show losses, the stock's current price near the consensus target of $10.50 suggests limited upside unless profitability improves or new ventures accelerate. Investors should weigh the high-risk, high-reward profile amid volatile earnings.